Last reviewed · How we verify
mg sulphate
Magnesium sulphate works by blocking calcium channels in the body, which helps to relax muscles and improve blood flow.
Magnesium sulphate works by blocking calcium channels in the body, which helps to relax muscles and improve blood flow. Used for Pre-eclampsia prevention and treatment, Asthma exacerbation treatment.
At a glance
| Generic name | mg sulphate |
|---|---|
| Also known as | mgso4 |
| Sponsor | Ain Shams University |
| Drug class | Calcium channel blocker |
| Target | Calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular, Obstetrics |
| Phase | Phase 3 |
Mechanism of action
Magnesium sulphate is a calcium channel blocker that acts on the smooth muscle cells of blood vessels, causing vasodilation and reducing blood pressure. It also has a direct effect on the uterus, causing relaxation of the uterine muscles and preventing contractions.
Approved indications
- Pre-eclampsia prevention and treatment
- Asthma exacerbation treatment
Common side effects
- Flushing
- Headache
- Dizziness
- Nausea
- Vomiting
- Muscle weakness
- Fatigue
- Rash
- Itching
- Hypotension
Key clinical trials
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (PHASE2)
- A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea
- A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health (NA)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial (PHASE2)
- Iron Absorption and Losses in Young South African Women Living Without and With Overweight and Obesity (NA)
- Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine (PHASE3)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mg sulphate CI brief — competitive landscape report
- mg sulphate updates RSS · CI watch RSS
- Ain Shams University portfolio CI